COMBINATION THERAPY Russian patent published in 2024 - IPC A61K31/18 A61K45/06 A61K31/44 A61K31/4523 A61K31/519 A61K31/5377 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions discloses a pharmaceutical combination containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, and (b) trametinib or a pharmaceutically acceptable salt or solvate thereof, where trametinib solvate is presented in the form of dimethyl sulfoxide solvate, for the treatment of cancer, wherein the cancer is characterized by a mutation selected from the group consisting of a BRAF, NRAS, KRAS mutation, and combinations thereof, wherein the compound of formula (I) is administered at a dose of about 50 to about 1,200 mg per day and trametinib is administered at a dose from about 0.125 mg to about 10 mg per day. Also the use of a compound which is a compound of formula (I) is disclosed.

(I)

EFFECT: provision of therapy for the treatment of cancer and, in particular, tumours with a KRAS mutation and/or tumours with a NRAS mutation, which provides effective and long-term treatment with good tolerance for patients suffering from cancer, in particular tumours with a KRAS and NRAS mutation -mutant tumours.

19 cl, 21 dwg, 7 tbl, 6 ex